ISAGRO AS OF DECEMBER 31ST, 2016

Conference Call
Milan, March 15th, 2017









2016: IN A STILL DIFFICULT YEAR FOR THE MARKET, ESPECIALLY IN SOUTH AMERICA ...

- In 2016, still unfavorable conditions for the Crop Protection market to recover:
 - adverse climatic conditions in some key markets
 - low prices of agricultural commodities
 - in Brazil, deep economic/financial crisis
- High level of inventory at distributor level
- Annual sales of main global players (Basf, Bayer, Dow, DuPont, Monsanto, Syngenta) lower than 2015 by around 5%

... ISAGRO HAS CONTINUED TO WORK FOR THE MID-TERM DEVELOPMENT PLAN

- Establishment of new companies in Mexico, Poland and Vietnam
- Strengthening of commercial structure of Isagro Argentina, Isagro Brasil, Isagro Shanghai and Isagro USA
- Hiring of new resources
- Production efficiency within manufacturing plants
- Continuation of new products / molecules development
- Agreements with Third Parties for the exploitation of Intellectual Property
- Despite lower sales, especially in Brazil

ISAGRO AS OF DECEMBER 31ST, 2016 Agenda

FACTS & FIGURES

BACK-UP

RESULTS AS OF DECEMBER 31ST, 2016


MAIN EVENTS


ISAGRO IN THE STOCK MARKET





2016 HAS BEEN, AS ANTICIPATED, A YEAR OF "CONSOLIDATION"

Consolidated data (€ million)











Isagro as of December 31st, 2016

EBITDA HAS BEEN AFFECTED BY "BRAZIL" AND "DEVELOPMENT OF COMMERCIAL ORGANIZATION" EFFECTS ...





... WITH NET FINANCIAL DEBT STILL LOWER THAN NET WORKING CAPITAL



PERSPECTIVES FOR 2017

■ Though achieved in a difficult year, 2016 results are encouraging as for the implementation of our Strategic Guidelines

2017 results:

- will depend, at revenues level, upon (i) the normalization of market/climatic conditions, mainly in the Americas, and (ii) the realization of revenues from new agreements with Third Parties for the exploitation of our I. P.
- will reflect, at cost/capex level, (a) the full year impact of 2016 newly hired resources, (b) the continuation of the strengthening of the global commercial organization and (c) the continuation of investments for new products / molecules


CONFIRMATION OF THE OBJECTIVE OF 200 MILLION EURO REVENUES IN THE MID-TERM

Based on our Strategic Guidelines:

- 1 DISCOVERY OF NEW MOLECULES BY OURSELVES
- DEVELOPMENT OF NEW MOLECULES MOSTLY THROUGH ATTRIBUTION OF RIGHTS TO "MAIN DEVELOPER(S)" WHILE RETAINING RIGHTS FOR ISAGRO ON SELECTED SEGMENTS/MARKETS
- 3 VALUE EXTRACTION FROM OUR I.P. ALSO THROUGH LICENSING
- 4 GROWTH IN THE BIOSOLUTIONS BUSINESS
- 5 OPPORTUNISTIC DEVELOPMENT OF OFF-PATENTED PRODUCTS
- 6 EXPANSION OF OUR GLOBAL COMMERCIAL ORGANIZATION



"UN-EXPRESSED" VALUE OF ISAGRO'S SHARES: MARKET CAP < BOOK VALUE < N.A.V.



- (1) Generating ~30€m annual sales
- (2) Generating ~45€m annual sales
- (3) Including Biofumigant (significant sales from 17/18). Existing business generating ~20 €m annual sales
- (4) Generating ~35€m extragroup annual sales
- (5) New broad spectrum fungicide originated by Isagro and being co-developed with FMC Corporation, with significant revenue starting from 2022/2023.
- (6) Based on share prices as at March 13th, 2017

3 MESSAGES TO INVESTORS

- Current market cap (45 €M) < Equity book value (102 €M) < N.A.V.
- 2016 multiples indicate stock price penalization vs. "peers"

	EV/Sales	EV/EBITDA	P/E
Syngenta*	3.1x	15.2x	26.2x
Recordati*	5.1x	15.6x	26.5x
ISAGRO**	0.7x	6.0x	16.5x

Moreover, "unjustified" spread between Ordinary and Growth Shares ("Azioni Sviluppo")

<u>Memo</u>: Growth Shares yield a 20% extra-dividend vs. Ordinary Shares and are automatically converted into Ordinary Shares if the Controlling Subject loses control and in any case of compulsory public offer

^{*} Source: Banca IMI

^{**} Based on stock prices as at March 13th, 2017

ISAGRO AS OF DECEMBER 31ST, 2016 Agenda

1 FACTS & FIGURES

BACK-UP

RESULTS AS OF DECEMBER 31ST, 2016

MAIN EVENTS


ISAGRO IN THE STOCK MARKET



CONSOLIDATED REVENUES


€ million


REVENUES BREAKDOWN BY PRODUCT CATEGORY



REVENUES BREAKDOWN BY REGION

(AGROPHARMA ONLY)






CONSOLIDATED P&L

€ million

	2016	2015	Varia	nces
REVENUES	149.7	156.0	-6.3	-4%
Of which : Licensing	5.9	7.0	-1.1	
EBITDA	16.2	19.5	-3.3	-17%
% ON REVENUES	10.8%	12.5%		
Depreciation & amortization	(9.3)	(9.7)	+0.4	
EBIT	6.9	9.8	-2.9	n/s
Financial items	(0.7)	(1.1)	+0.4	
Gain/(loss) from hedging on copper and EUR/USD	0.7	(1.3)	+2.0	
RESULT BEFORE TAXES	6.9	7.4	-0.5	n/s
Current and deferred taxes	(3.9)	(4.0)	+0.1	
NET RESULT FROM CONTINUING OPERATION	NS 3.0	3.4	-0.4	n/s
Net result of discontinued operations	(0.3)	(0.3)	-	_
NET RESULT	2.7	3.1	-0.4	n/s

CONSOLIDATED BALANCE SHEET





^{*} Net of Severance Indemnity Fund for 2.7 € m

^{* *} Net of Severance Indemnity Fund for 3.0 € m

P&L OF OPERATING COMPANIES

€ million

ISAGRO GROUP (consolidated)		Isagro S.p.A. (holding Co.)	Isagro Asia (at 100%)	Isagro Colombia (at 100%)	Isagro España (at 100%)	Isagro USA (at 100%)	
149.7	REVENUES	103.0	43.5	4.5	11.7	6.1	
156.0	Memo: 2015	108.7	45.7	3.9	11.3	5.5	
16.2 19.5	EBITDA Memo: 2015	9.8	8.6	0.7	1.0	(2.2)	
2.7	NET RESULT	(0.7)	5.3	0.2	0.8	(2.1)	
3.1	Memo: 2015	3.4	5.5	(0.4)	0.7	(1.5)	

BALANCE SHEET OF OPERATING COMPANIES

€ million

ISAGRO GROUP (consolidated)		Isagro S.p.A. (holding Co.)	Isagro Asia (at 100%)	Isagro Colombia (at 100%)	Isagro España (at 100%)	Isagro USA (at 100%)	
68	NET CURRENT ASSETS	45	20	1	1	5	
87	NET FIXED ASSETS *	101	5	0	0	0	
155	NET INVESTED CAP.	146	25	1	1	5	
147	Memo: 12.31.2015	138	23	1	1	8	
	FINANCED BY:						
102	EQUITY	87	35	1	1	1	
100	Memo: 12.31.2015	89	30	1	1	1	
53	NFP at debt/(credit)	59	(10)	0	(0)	4	
47	Memo: 12.31.2015	49	(8)	1	(0)	6	

^{*} Net of Severance Indemnity Fund

ISAGRO AS OF DECEMBER 31ST, 2016 Agenda

1 FACTS & FIGURES

BACK-UP

RESULTS AS OF DECEMBER 31ST, 2016

MAIN EVENTS

ISAGRO IN THE STOCK MARKET

MAIN EVENTS

- Establishment of Isagro Mexicana, Isagro Poland, Isagro Vietnam and strengthening of Isagro Argentina, Isagro Brasil, Isagro Shanghai, Isagro USA
- Finalization of long-term marketing and development agreement of the proprietary fungicide Kiralaxyl with Gowan Crop Protection Limited in November 2016
- Ordinary Redundancy Fund in Aprilia and Bussi plants
- Appointment of new Independent Director
- Appointment of new Board of Statutory Auditors

ISAGRO AS OF DECEMBER 31ST, 2016 Agenda

1 FACTS & FIGURES

BACK-UP

RESULTS AS OF DECEMBER 31ST, 2016


MAIN EVENTS

ISAGRO IN THE STOCK MARKET



UNJUSTIFIED SPREAD BETWEEN ORDINARY AND GROWTH SHARES

In the last 12-month period: ~14.2 million Ordinary Shares and ~7.1 million Growth Shares traded



*Growth Shares are a new category of special shares, issuable by companies having a Controlling Subject, which against the absence of voting right:

- grant an extra-dividend vs. Ordinary Shares (20% in the case of Isagro);
- are automatically converted into Ordinary Shares in the ratio 1:1 if the controlling Subject loses controlling Subject los

MARKET CAPITALIZATION LOWER THAN BOOK VALUE

	Price as of March 13 th , 2017 (Euro per share)	Market Capitalization (Euro/million)
ORDINARY SHARES	1.25	30.7
GROWTH SHARES	1.02	14.4
MARKET CAPITALIZATION		45.1
EQUITY BOOK VALUE		102.1*
	Market capi	talization < Equity Book Value

^{*} Book value of net fixed assets significantly lower than realizable market value





For information:

Ruggero Gambini

Chief Financial Officer

tel. (+39) 02.40901.280

Erjola Alushaj

IR Manager

& Financial Planner

tel. (+39) 02.40901.340







email: ir@isagro.com

www.isagro.com

«Disclaimer»

Estimates, considerations, statements and opinion, except for what referring to actual figures, are to be considered as data, estimates, considerations, statements and opinion regarding future, and have been elaborated and stated on the basis of available information and/or on the basis of those information considered the most reliable and/or the most reasonable.

Such data, estimates, considerations, statements and opinion could prove to be incomplete and/or wrong and they incorporate elements of risk of uncertainty, beyond the company control. For such reasons, actual results may prove to differ versus data, estimates, considerations, statements and opinion contained in such presentation.

Any reference to Isagro products is to be considered exclusively as general information about the group activity and is not to be intended, under any circumstances, as invitation to employ or propose the employment of such products.

Such data, estimates, considerations, statements and opinion are not to be considered as a proposal of investment, under any circumstances, in Isagro's shares.